Archive

Posts tagged under: big data

Connect with MDCPartners at the Immuno-Oncology Summit 2017

Connect with MDCPartners at Immuno-Oncology Summit 2017 from August 28 to September 1, 2017 in Boston, MA. Visit MDCPartners at booth #32 to discover next generation targeted immunotherapies and find new ways to navigate clinical data and overlap internal data with MDCPartners’ public data cloud.

Join us in Boston

Would you like to know how our clinical business intelligence software ta-Scan or our other data solutions can help with your company’s data challenges? Then feel free to pop by booth #32 or make an appointment with MDCPartners’ Director of Business Development, North America Matt Tumasz and/or Strategic Analyst, Oncology, Dr. Jonathan Crowther. They will gladly show you our state of the art tools.

Register Today

Secure your place now if you want to connect with the ta-Scan team in Boston. MDCPartners has arranged for an exclusive discount on CHI’s Immuno-Oncology Summit. Use promo code MDC when registering to receive your $200 registration discount. This discount applies to conference programs only and cannot be used on short courses, combined with other offers, or transferred.

How to register:
Online: https://chidb.com/reg/imx/reg.asp
By Phone: +1 781-972-5472

Immuno-Oncology Summit 2017 Program

Now in its fifth year, the Immuno-Oncology Summit will return to Boston again this August 28-September 1 with the goal of supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers.

This year’s IO Summit has been designed to give attendees a complete picture of the field and its advances with 12 conference tracks, 1 in-depth training seminar, and 4 instructional short courses. Topics include immunotherapy discovery, development, biomarkers, and translational oncology as well as emerging topic areas such as cancer vaccines, oncolytic viruses, and advances in synthetic biology techniques. Overall, this event provides a focused look at how researchers are applying new science and technology in the development of effective and safe immunotherapies.

Download the digital brochure for full details.

We look forward to seeing you in Boston!

BIG Data: How Pharma Can Use it to its Advantage

In this European Pharmaceutical Manufacturer Magazine opinion article, MDCPartners’ founder and CEO, Mireille De Cré, explains how pharma R&D can make the most of the big data revolution.

The big data hype train has been gaining momentum for a number of years and its rise has been well documented. However, pharma companies are still perplexed by the scope of what big data can do, and why, how and where they should use big data tools to their advantage.

With focus moving away from sheer volume of data and inherent variability and complexity of large unstructured datasets towards user-friendly analytic tools that can help businesses plan for the future, now is the time for big, small and medium size pharma to seize the ‘big data’ opportunity.

What is clear is that big data is here to stay and will continue to have a growing influence in terms of its impact to business decision making across a number of sectors. Some of those in pharma are firmly grasping the opportunity that analytics-based decision making can bring… And those that aren’t will need to catch up before they lose out.

Read more in the European Pharmaceutical Manufacturer Magazine article: http://www.epmmagazine.com/opinion/big-data/

NEWS RELEASE: MDCPartners launches new ta-Scan software that ‘will revolutionize’ the way pharmaceutical companies plan for the future

Antwerp, Belgium | 24 January 2017 – MDCPartners today launches ta-Scan 5, an update of its global web-based platform that analyses clinical trial data. The new platform is set to revolutionize the way pharmaceutical researchers plan for the future, by providing unrivaled insights that will help inform future business decisions.

The new ta-Scan 5 is the first software of its kind to use exceptionally powerful algorithms to analyse clinical data from multiple global public sources in its patented Trial Cloud®. The new version 5 will mean that pharmaceutical companies are able to obtain more valuable insights on clinical research than ever before, via a more streamlined process.

The software will allow companies to go into more detail on clinical trial research than ever before, with access to over 250,000 clinical trials and 7 million scientific and clinical experts. This will provide unique insights on specific compounds, research institutes, clinical centers, patient populations, key investigators and competitor analysis to help strategic decision making.

“We believe the opportunity in clinical business intelligence is the freedom to look at data from multiple sources, from any region, combined into one system that’s easy to use. The new ta-Scan 5 does just that – it taps into vast amounts of information and provides comprehensive analysis that can be broken down easily. Pharmaceutical companies are now starting to realize their opportunities in gathering the most valuable business intelligence, and I believe the ability of this software will fundamentally change the way clinical research is planned and executed across the industry,” comments David Cocker, CSO for MDCPartners, who is presenting this week at the SCOPE Summit in Miami, Florida.

“For the first time ever, MDCPartners has been able to simplify complex trial-related queries and perform deep analysis using the most powerful algorithms yet. Using Real World Solutions, we can link internal and external information together through a portal, to generate a comprehensive landscape and get a full view of where the competing trials are conducted, and where the patient populations are. Before, we couldn’t link this information, now it is at our fingertips,” comments Dr Bart Naudts, Lead Data Architect at MDCPartners.

The ta-Scan web platform has been used by pharmaceutical and biotech researchers for the last decade. It has transformed and advanced the process of intelligence gathering and analyzes across the industry.

Media Enquiries

MDCPartners
Mireille De Cré
mireille.decre@mdcpartners.be
+32 (0) 3 870 97 50

Tonic Life Communications
Stan Jackson / Chrissie Hannah
stan.jackson@toniclc.com / chrissie.hannah@toniclc.com
+44 (0) 774 771 8279 / +44 (0)777 253 4646

***ENDS***

Notes to Editors

About ta-Scan

ta-Scan is an intelligence web platform for clinical development, which analyses data for trial planning, expert profiling, disease landscape and competitive intelligence, for researchers in the pharmaceutical and biotech industry. It was launched nearly a decade ago to transform and advance the intelligence gathering and analyses that enable clinical development.

Powerful algorithms enable researchers to bypass print publications, restrictive registries and dense databases for the insights they need to make evidence-based decisions. With ta-Scan, users can locate key opinion leader (KOL) associations, investigators with specific therapeutic experience, or institutes with the capacity to conduct complex protocols.

To find out more about ta-Scan, please visit: www.ta-scan.com/product

About ta-Scan 5

ta-Scan 5 is the updated model of ta-Scan, which was recently launched by MDCPartners at the SCOPE Summit in Miami, Florida, in January 2017. It offers a uniquely streamlined and simplified intelligence gathering process and improves data access and value, allowing for a more intuitive, business-oriented workflow.

ta-Scan 5 features a refined and robust search engine tool which activates alternative information pathways with the flexibility to adjust query filters with ease. The number and potential combination of trial-related queries is unrestricted, meaning that hundreds of data classes are semantically connected that can be accessed by one query.

To find out  more about ta-Scan 5, please visit: https://vimeo.com/mdcp/ta-scan5

About MDCPartners

Founded in 1999, MDCPartners specialises in business intelligence and strategic consultancy for the pharmaceutical and biotech industry. They combine drug development expertise with the latest data sciences to provide clinical trial optimisation, medical expert identification and competitive intelligence.

MDCPartners is a leader in the field of data mining and semantic processing. With their patented data solutions, their clients transform millions of dispersed data points into meaningful intelligences.

MDCPartners is headquartered in Antwerp, Belgium, with sales offices in the USA and Japan. It has three flagship products for global pharmaceutical data solutions, including:

  • ta-Scan: the flagship product ta-Scan is a web business intelligence platform that analyses clinical development programmes, trial and site data, and involvement of medical experts
  • normScan: the medical device standards monitoring tool, normScan, is tailored to the client’s medical device portfolio. normScan tracks all relevant device standards and regulatory documents that have been published or are in development
  • Real World Solutions: an evolving area of business for MDCPartners are the customised data solutions, which tap into a robust inventory of algorithms and unique visualisation tools. Users can gain optimal insights from data either as stand-alone or combined with public data

To find out more about MDCPartners, please visit: www.mdcpartners.be

MDCPartners Innovation Partner Big Data in Precision Medicine Washington

Big Data in Precision Medicine

With ESMO 2016 coming to a close in Copenhagen, MDCPartners is getting ready for their next stop: we are this year’s Innovation Partner of the Big Data in Precision Medicine meeting, which will take place in the Capital Hilton in Washington, D.C. on November 1-2, 2016.

This meeting attracts 250-300 senior executives from across the drug development sector including Big Pharma, biotech, leading solution providers, government, healthcare and academia. The meeting addresses the opportunities and challenges of big and real-world data, and how machine learning and cognitive computing can be applied in the context of drug development. View the meeting’s streams and the meeting agenda here.

Private Clinical Trial Data in the Real-World Data Context

On Tuesday November 1 at 9:30 AM, MDCPartners’ Chief Scientific Officer David Cocker will present our findings on “The value case of private pharma clinical trial data in the real-world data context”.

Real-world data (RWD) is generally the term used to refer to any data which is collected outside of randomized clinical trials (RCT). The data can be from sources including patient data from hospitals and clinicians. The premise is that RWD combined with information from RCTs can provide better research outcomes and improved healthcare.

Unfortunately, available clinical trial information data is really not that big. Often it is also dispersed and contradictory, and includes duplicates through multiple entries that are not verified and/or matched. Many transformative actions with data are frequently heralded as a big data panacea long before any analytical conclusion can be applied.

This presentation will explore the challenges faced when approaching the question of clinical trial data merging and its interoperability with public clinical trial data for creating valuable insights for study placement.

Meeting Up

ta-Scan’s data team will be present in Washington, D.C. as well to show the precision medicine experts how our clinical business intelligence software ta-Scan can leverage today’s medical big data challenges.

If you want to learn more about our software solutions, you can meet us personally during the exhibition at booth #1 or make an appointment with CSO David Cocker or Strategic Data Analyst, Oncology Jonathan Crowther.

Where can you find us in 2016?

First of all, a happy New Year and our best wishes to you all! 2016 has nearly been launched, but we already have some big events in store for this year. We’ll keep sharing innovative knowledge with our healthcare business network at expert meetings. Below you can find a chronological list of conferences we will be attending this year. You can also find us exhibiting our clinical business intelligence software ta-Scan there. We hope to meet you there!

SCOPE Summit

February 23-25 | Miami, Florida

SCOPE 2016 Summit for Clinical Operations Executives

The 7th Annual SCOPE Summit for clinical operations executives will offer three stimulating days of in-depth discussions in twelve different conferences, four pre-conference workshops and two symposia focused on issues related to each aspect of clinical trial planning and management: Data Integration, Feasibility, Site Selection and Management, Patient Engagement, Recruitment and Retention, Mobile Tech, Project Management, Outsourcing, Forecasting, Budgeting and Contracting, Quality (QbD) in Trial Conduct, Risk-Based Monitoring, Post-Marketing Studies, Observational Research, Statistics and Biomarker-Driven Trials. Click here to view the meeting program.

Learn more about Advanced Feasibility Modelling from David Cocker’s presentation, and meet the ta-Scan team personally at booth 506 & 508!

Oncology Leaders Forum

April 5-6 | Boston, Massachusetts

Oncology Leaders Forum 2016 Phacilitate

Join the most senior oncology event in the pharmaceutical sector where 88% of the audience are Director-level and above for two days of strategic thinking and networking. Recognized as the leader by the leaders, the Oncology Leaders Forum is the event of choice for senior translational and clinical oncology R&D executives driving the development, registration and launch of novel cancer therapeutics of all classes, plus companion diagnostics. Click here to view the meeting agenda.

Hear David Cocker’s introductory keynote:

“The evolution towards precision: a chronology of transition”
Standards of care. What’s changing in therapy focus?
•  Scenario-based enrollment: forecasting and validation
•  Footprint of global trial activity. Who is generating the data? KOL ranking
•  Where will I be conducting my next trial?
•  The death of the longitudinal drug development paradigm

Clinical Trial Innovation Summit

May 9-11 | Boston, Massachusetts

Clinical Trial Innovation Summit 2016 Banner
Cambridge Healthtech Institute’s Fifth Annual Clinical Trial Innovation Summit will bring together leaders from across pharma, biotech and academia to share case studies and best practices on effective clinical trial management and vendor oversight. The 2016 program focuses on key issues and opportunities in the clinical trial industry, including Patient Recruitment, Site Selection, Data Integration, Existing Data Sources, Mobile Tech, Project Management, Outsourcing, Vendor Management, Budgeting and Contracting, Quality (QbD) in Trial Conduct, Risk-Based Monitoring and Clinical Auditing. Click here to view the final meeting brochure.

Immunotherapy Forum Europe

September 21-22 | Berlin, Germany

Phacilitate Leaders Europe Immunotherapy Europe Berlin 2016

Immuno-oncology is the hot topic across the life science sector following a range of recent successes and approvals. Be part of this new event and meet leaders from across the sector to discover the path to commercialization in Europe. Click here to view the meeting agenda.

Big Data in Precision Medicine

November 1-2 | Washington, D.C.

MDCPartners Big Data in Precision Medicine Conference

Meet all the key stakeholders under one roof: Pharma, Biotech, CROs, Health Systems, CMOs and Government. Key themes will include: integrating big data across drug development, big data in translational science and clinical trialsprecision medicine analytics ecosystem, big data enabling the future of healthcare. Click here to view the meeting agenda.

More info coming soon!

Do you want to stay updated on upcoming ta-Scan events and product and industry news? Keep an eye on our website, or follow us on LinkedIn or Twitter and never miss out.

David Cocker’s keynote on Data-Driven Decision-Making in Immunotherapy in Washington

7-8 October 2015 | Ronald Reagan Building and International Trade Center, Washington DC

MDCPartners and the ta-Scan clinical business intelligence team are pleased to announce a keynote presentation by David Cocker on the third Big Data in Clinical Development conference in Washington.

Join us on Wednesday 7 October at 9:30 AM, when David Cocker will give a keynote presentation on Data-Driven Decision-Making in Immunotherapy.

Also meet Matt and David in the exhibition hall (booth # 11) to get the latest updates on ta-Scan, or contact us to make an appointment.

Click here to see the complete meeting agenda.

Phacilitate Big Data Banner

Categories

 

Tags

 

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page